A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link with the drugs has not been established. That is the conclusion of a retrospective study published online on Jan. 30 in JAMA Ophthalmology.
The study focused on nine patients who had experienced vision problems while using semaglutide (brand names Wegovy and Ozempic) and tirzepatide (brand names Mounjaro and Zepbound).
The paper is one of several in the past year that have documented vision problems in patients using these drugs. Several patients have presented with a medical condition called nonarteritic anterior ischemic optic neuropathy (NAION), a non-inflammatory disease of small blood vessels in the anterior portion of the optic nerve. The condition occurs…